根据名称进行药物检索

Gengraf Capsules 与 Zithromax (Azithromycin Single-Dose Packet)

Gengraf Capsules 与 Zithromax (Azithromycin Single-Dose Packet)互相作用以及同时服用的可能性。

检测结果:

Gengraf Capsules <> Zithromax (Azithromycin Single-Dose Packet)

现实性: 16.04.2022 评论家: 医学副博士Shkutko P.M., in

在该服务的官方手册中，已注明相关研究结果统计规定的互相作用。该互相作用或对患者健康引起不良后果，或起到良好效果。具体联合用药问题，需遵从医嘱。

用户:

阿齐可能很少增加的血液水平和影响的环孢菌素。联系您的医生如果您的状况改变或者如果你的经验增加的副作用，例如恶心、呕吐、腹泻、腹部疼痛、头晕、疲劳、头痛、震颤、抽搐发烧，喉咙痛，不寻常的瘀伤或流血，并增加或减少排尿。重要的是要告诉你的医生关于所有其他药物的使用，包括维生素和草药。不停止使用任何药物，没有第一个说你的医生。

医界专家:

监测：可用数据表明，阿齐可能很少增加的血液浓度的环孢菌素。该机构的相互作用尚未建立。其他大环内酯类抗生素比如克拉和红霉素妨碍清除cyclosporine通过抑制CYP450 3A4新陈代谢和P-糖蛋白流出，但阿齐是不知道到抑制。药物动力学研究健康的志愿人员和肾脏移植的患者也没有发现任何证据的临床显着的相互作用，并且阿齐了广泛的研究在治疗药诱导的牙龈增生没有报告的交互作用。尽管如此，有的已经分离的情况的报告显着增加cyclosporine的血液水平期间，共同给予与阿齐霉素。在一个报告，孢菌素槽的水平增加至178纳克/毫升(采取两个星期前在第一天的住院治疗)为400纳克/毫升三天后开始的头孢三嗪(1克IV每12个小时)以及阿齐(500毫克IV一天一次)以治疗肺炎的可能在一个42岁的肾脏移植的患者已经稳定在环孢霉素100毫克，一天两次，为期两年。他的药用量减少50％，并槽的水平恢复正常在医院天6和保持正常的三天后，当阿齐已经停产了。然而，在医院的第13天，孢菌素槽的水平降至76毫微克/毫升，这导致一个剂量增加回到100毫克每天两次。三天后,孢菌素槽的水平是在170纳克/毫升和保持在目标时测量的第19天，并在后续行动的三个星期之后的排放。混杂因素的情况下，包括活性感染和热，从而可以改变的水平和活动的CYP同功，以及伴随而来的药头孢三嗪，它已经与增加孢菌素水平大约2倍，在孤立的情况的报告。然而，该时间之间关系的中止霉素和减少药级别会牵连阿齐而不是头孢三嗪，这是不停止，直到医院天17. 其他未公布的报告的不良事件归咎于潜在的相互作用之间的霉素和环孢霉素包括耳鸣，海拔在血液的氮和尿素的血清肌酸酐和白细胞减少。

管理：谨慎和更密切监测cyclosporine的血液水平和肾功能可以最好在共同给予与阿齐，特别是在病人是老人或病危。患者应建议通知他们的医生如果他们的经验可能的迹象和症状的药的毒性，例如恶心、呕吐、腹泻、腹部疼痛、头晕、疲劳、头痛、震颤、和抽搐。

来源

Wadhwa NK, Schroeder TJ, O'Flaherty E, et al "Interaction between erythromycin and cyclosporine in a kidney and pancreas allograft recipient." Ther Drug Monit 9 (1987): 123-5
Spicer ST, Liddle C, Chapman JR, Barclay P, Nankivell BJ, Thomas P, O'Connell PJ "The mechanism of cyclosporine toxicity induced by clarithromycin." Br J Clin Pharmacol 43 (1997): 194-6
Kohan DE "Possible interaction between cyclosporine and erythromycin." N Engl J Med 314 (1986): 448
Freeman DJ, Martell R, Carruthers SG, et al "Cyclosporin-erythromycin interaction in normal subjects." Br J Clin Pharmacol 23 (1987): 776-8
Amsden GW "Macrolides versus azalides: a drug interaction update." Ann Pharmacother 29 (1995): 906-17
"Product Information. Sandimmune (cyclosporine)." Sandoz Pharmaceuticals Corporation, East Hanover, NJ.
Kwun WH, Suh BY, Kwun KB "Effect of azithromycin in the treartment of cyclosporine-induced gingival hyperplasia in renal transplant recipients." Transplant Proc 35 (2003): 311-2
"Product Information. Zithromax (azithromycin)." Pfizer US Pharmaceuticals, New York, NY.
Yee GC, McGuire TR "Pharmacokinetic drug interactions with cyclosporin (Part I)." Clin Pharmacokinet 19 (1990): 319-32
Nahata M "Drug interactions with azithromycin and the macrolides: an overview." J Antimicrob Chemother 37 ( Suppl (1996): 133-42
Boran M, Gunes Z, Doruk E, Gonenc F, Cetin S "Improvement in cyclosporine a associated gingival hyperplasia with azithromycin therapy." Transplant Proc 28 (1996): 2316
Wahlstrom E, Zamora JU, Teichman S "Improvement in cyclosporine-associated gingival hyperplasia with azithromycin therapy." N Engl J Med 332 (1995): 753-4
Citterio F, Di Pinto A, Borzi MT, et al. "Azithromycin treatment of gingival hyperplasia in kidney transplant recipients is effective and safe." Transplant Proc 33 (2001): 2134-5
Ptachcinski RJ, Carpenter BJ, Burckart GJ, Venkataramanan R, Rosenthal J "Effect of erythromycin on cyclosporine levels." N Engl J Med 313 (1985): 1416-7
Knower MT, LabellaWalker K, McFadden PM, Kantrow SP, Valentine VG "Clarithromycin for safe and cost-effective reduction of cyclosporine doses in lung allograft recipients." South Med J 93 (2000): 1087-92
Gupta SK, Bakran A, Johnson RW, Rowland M "Cyclosporin-erythromycin interaction in renal transplant patients." Br J Clin Pharmacol 27 (1989): 475-81
Cockburn IT, Krupp P "An appraisal of drug interactions with sandimmun." Transplant Proc 21 (1989): 3845-50
Fabre I, Fabre G, Maurel P, et al "Metabolism of cyclosporin A. Interaction of the macrolide antibiotic, erythromycin, using rabbit hepatocytes and microsomal fractions." Drug Metab Dispos 16 (1988): 296-301
Jensen CW, Flechner SM, Van Buren CT, et al. "Exacerbation of cyclosporin toxicity by concomitant administration of erythromycin." Transplantation 43 (1987): 263-70
Tokgoz B, Sari HI, Yildiz O, et al. "Effects of azithromycin on cyclosporine-induced gingival hyperplasia in renal transplant patients." Transplant Proc 36 (2004): 2699-2702
Nash MM, Zaltzman JS "Efficacy of azithromycin in the treatment of cyclosporine-induced gingival hyperplasia in renal transplant recipients." Transplantation 65 (1998): 1611-5
Ljutic D, Rumboldt Z "Possible interaction between azithromycin and cyclosporin: a case report." Nephron 70 (1995): 130
Kessler M, Louis J, Renoult E, et al "Interaction between cyclosporin and erythromycin in a kidney transplant patient." Eur J Clin Pharmacol 30 (1986): 633-4
Gersema LM, Porter CB, Russell EH "Suspected drug interaction between cyclosporine and clarithromycin." J Heart Lung Transplant 13 (1994): 343-5
Page RL 2nd, Ruscin JM, Fish D, Lapointe M "Possible interaction between intravenous azithromycin and oral cyclosporine." Pharmacotherapy 21 (2001): 1436-43
Ferrari SL, Goffin E, Mourad M, Wallemacq P, Squifflet JP, Pirson Y "The interaction between clarithromycin and cyclosporine in kidney transplant recipients." Transplantation 58 (1994): 725-7
Gomez E, Sanchez JE, Aguado S, Grande JA "Interaction between azithromycin and cyclosporin?" Nephron 73 (1996): 724
Murray BM, Edwards L, Morse GD, et al "Clinically important interaction of cyclosporine and erythromycin." Transplantation 43 (1987): 602-4
Sketris IS, Wright MR, West ML "Possible role of the intestinal p-450 enzyme system in a cyclosporine clarithromycin interaction." Pharmacotherapy 16 (1996): 301-5
Grino JM, Sabate I, Castelao AM, et al "Erythromycin and cyclosporine." Ann Intern Med 105 (1986): 467-8